Published in Clin Chem on April 01, 1996
Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer (2009) 1.08
Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer (1999) 1.05
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer (2016) 0.91
Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer (2001) 0.80
Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer. Clin Epigenetics (2016) 0.79
Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review. Postgrad Med J (2003) 0.77
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer. Biomed Res Int (2015) 0.77
Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Saudi Breast Cancer Patients as Prognostic and Predictive Indicator. Breast Cancer (Auckl) (2015) 0.75
Dwarf8 polymorphisms associate with variation in flowering time. Nat Genet (2001) 9.63
Mapping quantitative trait loci controlling milk production in dairy cattle by exploiting progeny testing. Genetics (1995) 9.26
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol (1998) 3.69
GAW12: simulated genome scan, sequence, and family data for a common disease. Genet Epidemiol (2001) 3.13
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol (1992) 2.91
Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol (1988) 1.84
Microsatellite mapping of the gene causing weaver disease in cattle will allow the study of an associated quantitative trait locus. Proc Natl Acad Sci U S A (1993) 1.77
Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol (1987) 1.59
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science (1995) 1.56
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B Trial. Eur J Cancer (1999) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med (1993) 1.52
Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol (2002) 1.49
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet (1996) 1.47
Microsatellite mapping of a gene affecting horn development in Bos taurus. Nat Genet (1993) 1.45
Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.44
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
[Male breast cancer. A review]. Ugeskr Laeger (1996) 1.40
Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients. J Clin Oncol (1995) 1.39
Chromosomal localization of the callipyge gene in sheep (Ovis aries) using bovine DNA markers. Proc Natl Acad Sci U S A (1994) 1.38
Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol (1999) 1.36
Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs (1998) 1.30
Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res (1978) 1.28
Right ventricular infarction: frequency, size and topography in coronary heart disease: a prospective study comprising 107 consecutive autopsies from a coronary care unit. J Am Coll Cardiol (1987) 1.26
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol (1996) 1.25
In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta (1999) 1.24
Liver resection and local ablation of breast cancer liver metastases--a systematic review. Eur J Surg Oncol (2011) 1.22
Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol (1977) 1.21
Cellular resistance to anthracyclines. Gen Pharmacol (1996) 1.19
Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol (1986) 1.19
Familial poliodystrophy, mitochondrial myopathy, and lactate acidemia. Neurology (1975) 1.17
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol (1998) 1.15
Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta (1997) 1.15
Right ventricular infarction: diagnostic value of ST elevation in lead III exceeding that of lead II during inferior/posterior infarction and comparison with right-chest leads V3R to V7R. Am Heart J (1989) 1.15
Rehabilitation of patients with chronic obstructive pulmonary disease. Exercise twice a week is not sufficient! Respir Med (2000) 1.13
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol (2008) 1.13
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol (2001) 1.11
Interpretation of the electrocardiogram in suspected myocardial infarction: a randomized controlled study of the effect of a training programme to reduce interobserver variation. J Intern Med (1992) 1.11
FISH analysis for chromosomes 13, 16, 18, 21, 22, X and Y in all blastomeres of IVF pre-embryos from 144 randomly selected donated human oocytes and impact on pre-embryo morphology. Hum Reprod (2003) 1.11
Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev (1995) 1.11
Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst (1992) 1.10
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol (2002) 1.09
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta (1997) 1.08
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol (1990) 1.06
Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. Br J Cancer (1986) 1.05
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer (2006) 1.03
Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer (1987) 1.03
Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A (1973) 1.02
P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim Biophys Acta (1992) 1.02
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol (1994) 1.02
Membrane transport of anthracyclines. Pharmacol Ther (1982) 1.00
Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol (1986) 1.00
Increase in nonspecific adsorptive endocytosis in anthracycline- and vinca alkaloid-resistant Ehrlich ascites tumor cell lines. J Natl Cancer Inst (1987) 1.00
Localization of the locus causing Spider Lamb Syndrome to the distal end of ovine Chromosome 6. Mamm Genome (1999) 0.98
Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol (1978) 0.98
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res (1983) 0.98
Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol (1996) 0.97
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol (1993) 0.97
The impact of trauma centre designation on open tibial fracture management. Ann R Coll Surg Engl (2013) 0.95
Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol (2000) 0.95
Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med (1988) 0.93
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer (1998) 0.93
Chemotherapy of advanced small-cell anaplastic carcinoma. Superiority of a four-drug combination to a three-drug combination. Ann Intern Med (1978) 0.93
Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res (1983) 0.93
Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial. Breast Cancer Res Treat (1993) 0.92
The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J Clin Oncol (1987) 0.91
Long-term survival in small cell carcinoma of the lung. JAMA (1980) 0.91
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer (2004) 0.91
Influence of surgical resection prior to chemotherapy on the long-term results in small cell lung cancer. A study of 150 operable patients. Eur J Cancer Clin Oncol (1986) 0.91
Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. Br J Cancer (1999) 0.91
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol (2001) 0.91
Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinomas from a multicenter trial. Cancer (1987) 0.90
Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev (1984) 0.89
Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res (1980) 0.89
Identification of four variants in the tryptophan hydroxylase promoter and association to behavior. Mol Psychiatry (1999) 0.89
A Danish randomized trial comparing breast-preserving therapy with mastectomy in mammary carcinoma. Preliminary results. Acta Oncol (1988) 0.89
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (1990) 0.89
Bone-marrow examination in the staging of small-cell anaplastic carcinoma of the lung with special reference to subtyping. An evaluation of 203 consecutive patients. Cancer (1977) 0.88
Formation of biologically active peptides. Proc R Soc Lond B Biol Sci (1980) 0.88
Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol (1987) 0.88
Occupational accidents aboard merchant ships. Occup Environ Med (2002) 0.88
A de novo cystic fibrosis mutation: CGA (Arg) to TGA (stop) at codon 851 of the CFTR gene. Genomics (1991) 0.87
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol (2002) 0.87
ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines. Biochim Biophys Acta (1997) 0.86
Low maternal but normal fetal prolactin levels in cigarette smoking pregnant women. Acta Obstet Gynecol Scand (1984) 0.86